Latest Industry Insights
Industry Insight
Breath Test for Cancer: Biomarker Screening is Underway
The thought that compounds in the breath could be measured and assessed to diagnose different aspects of pathology is an exciting prospect. To learn more about the breathalyzer platform being used in clinical trials to detect early cancer biomarkers, we spoke to Chris Claxton, head of investor relations at Owlstone Medical.
Industry Insight
Superficial Radiation Therapy: A Non-surgical Treatment for Non-melanoma Skin Cancers
Skin cancer can be broadly split in to two types: melanoma and non-melanoma. The most common non-melanomas include basal cell carcinoma and squamous cell carcinoma, for which the main treatment is surgery. However, other non-surgical options are emerging, including superficial radiation therapy (SRT), a unique type of photon radiotherapy.
Industry Insight
The Vision for Multi-organ Human-on-a-Chip Models
The development of organ-on-a-chip models aims to reduce the (expensive) high drug failure rates that exist in clinical trials. A Florida biotech firm recently reported that their multi-organ “human-on-a-chip” system maintains cellular viability over 28 days in serum-free conditions, using a pumpless system. To learn more about the vision for multi-organ “human-on-a-chip” models, we caught up with James Hickman, Chief Science Officer of Hesperos Inc.
Industry Insight
Is Off-the-Shelf Immunotherapy the Way Forward?
An “off-the-shelf” immuno-oncology product has been developed whereby T cells are derived from healthy donors, bypassing limitations related to high pricing and limited market access.
Industry Insight
FISH Probes Approved for Targeted Genome Analysis in Cancer
Recently, the FDA granted de novo classification for eight fluorescence in situ hybridisation (FISH) probes for myelodysplastic syndromes and acute myeloid leukaemia. We spoke with Steve Chatters, Director of Medical Affairs at Oxford Gene Technology, to learn more about the application of FISH probes in modern medicine.
Industry Insight
The Booming Business of Neurotoxin Therapy
Botulinum neurotoxins are widely used in both therapeutic and cosmetic applications, but Ipsen says that their new rBoNT-E toxin is a step up from compounds based on the much more widely used serotype A toxin. We spoke to Ipsen Senior Vice President Neurosciences R&D, Philippe Picaut, to find out more.
Industry Insight
Harnessing AI in a Battle Against Aging
A recently announced collaboration between Juvenescence, Ltd., and NetraMark Corp. has yielded a new joint venture, NetraPharma, which aims to fight aging-related conditions. We spoke with NetraMark founder Dr. Joseph Geraci to find out more about how the process of targeting and treating neurodegenerative disorders will be radically changed by AI.
Industry Insight
Biosimilar Surge Driving Need for Antibody Characterization
Accurate protein characterization is particularly important in the biopharmaceutical industry, where product modifications can affect efficacy and safety. Here, we speak to Matthew Lauber, a consulting scientist who elaborates on the importance and challenges of biotherapeutic protein characterization, and discusses different techniques used for charge variant analysis.
Industry Insight
Challenges and Promises of Translational Informatics
In this blog, Fan Fan, Vice President of Product Management at DNAnexus, a company focused on biomedical informatics and data management, discusses trends in translational informatics and how it has begun to revolutionize healthcare.
Industry Insight
The Biggest Challenges for Data Integrity
Ensuring that data is reliable, reproducible, and therefore valuable means companies in both regulated and non-regulated spaces must keep data integrity at the heart of their informatics operations. We talked to John Zenk, Validation Services Manager at laboratory informatics consultancy CSols, Inc, to find out what the biggest concerns in data integrity are and how companies can take steps to overcome these challenges.
Advertisement